Compare Gilead Sciences, Inc. (GILD) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SYSCO Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.94 (market cap $163.51B), while SYSCO Corporation trades at $82.46 (market cap $38.60B). The key difference: Gilead Sciences, Inc. is far larger — about 4.2× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| GILD | SYY | |
|---|---|---|
Market Cap | $163.51B | $38.60B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $91.16 |
52-Week Low | $108.22 | $69.30 |
Enterprise Value | $178.05B | $52.08B |
Dividend Yield | 2.49% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SYY trades at $82.32, down 0.64% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. Revenue growth remains steady, reaching $81.37B in 2025, while net income margin is 2.08%. The company maintains positive cash flow and announced a $0.55 dividend for July 2026.
Outlook is positive with a consensus price target of $83.67, though risks include margin pressure and debt levels. The stock offers value with a P/S of 0.47, but investors should monitor Q2 2026 earnings and industry headwinds. Institutional sentiment is bullish, with 60% buy ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
